Methods for treating progressive cognitive disorders related to neurofibrillary tangles

Abstract

The described invention provides methods for treating or preventing progression of a progressive cognitive disease, disorder or condition, and methods for improving resilience of cognitive function in a subject in need thereof.

What is claimed is: 
     
         1 . A method for treating a progressive cognitive disorder, the method comprising the step of:
 (a) administering to a subject in need thereof a first composition comprising
 (i) a phosphorylated tau accumulation-modulating amount of a leptin composition, or a pharmaceutically acceptable salt thereof, and 
 (ii) a pharmaceutically acceptable carrier, and 
   (b) modulating accumulation of phosphorylated tau in cerebrospinal fluid of the subject.   
     
     
         2 . The method according to  claim 1 , wherein the progressive cognitive disorder is selected from the group consisting of progressive supranuclear palsy, dementia, dementia pugilistica, Creutzfeldt-Jakob disease, frontotemporal dementia, Pick's disease, and FTDP-17 (parkinsonism) corticobasal degeneration. 
     
     
         3 . The method according to  claim 1 , wherein the leptin composition is a leptin, or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The method according to  claim 1 , wherein the leptin composition is a leptin mimic, or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The method according to  claim 1 , wherein the leptin composition is a leptin derivative, or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method according to  claim 1 , wherein the leptin composition is a leptin agonist, or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method according to  claim 1 , wherein the phosphorylated tau accumulation modulating amount is an amount from about 0.01 mg/kg body weight to about 100 mg/kg body weight. 
     
     
         8 . The method according to  claim 1 , wherein the first composition further comprises a second therapeutic agent. 
     
     
         9 . The method according to  claim 8 , wherein the second therapeutic agent is at least one of an antibiotic, an anti-fungal agent, an antiviral agent, an anti-protozoal agent, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an anti-oxidant; a hormone; a vitamin; an antihistamine agent. and a chemotherapeutic agent. 
     
     
         10 . The method according to  claim 1 , wherein the progressive disorder comprises accumulation of neurofibrillary tangles in brain. 
     
     
         11 . A method for improving resilience of cognitive function in a subject in need thereof, the method comprising the step of
 (a) administering to the subject a composition comprising:
 i. a cognitive function-enhancing amount of a leptin composition, and 
 ii. a pharmaceutically acceptable carrier; and 
   (b) modulating accumulation of phosphorylated tau in cerebrospinal fluid of the subject.   
     
     
         12 . The method according to  claim 11 , wherein the leptin composition comprises at least one of a leptin, a leptin mimic, a leptin derivative, an AMP-dependent protein kinase activator, a leptin agonist, a leptin blocker, a mimic of a leptin blocker, a leptin antagonist, an AMP-dependent protein kinase inhibitor; or pharmaceutically acceptable salts thereof. 
     
     
         13 . The method according to  claim 11 , wherein the leptin composition further comprises a second therapeutic agent. 
     
     
         14 . The method according to  claim 13 , wherein the second therapeutic agent is at least one of an antibiotic, an anti-fungal agent, an antiviral agent, an anti-protozoal agent, a steroidal anti-inflammatory agent, a non-steroidal anti-inflammatory agent, an anti-oxidant; a hormone; a vitamin; an antihistamine agent. and a chemotherapeutic agent.